drugset
Drugs / iC9.GD2.CAR.IL-15 T cells
last change Jun 2023 re-read 3 minutes ago

iC9.GD2.CAR.IL-15 T cells

Cell therapy

Developed for
neuroblastoma · non-small cell lung carcinoma · osteosarcoma · small cell lung carcinoma
Investigated by
Bellicum Pharmaceuticals · UNC Lineberger Comprehensive Cancer Center · United States Department of Defense · M.D. Anderson Cancer Center · National Cancer Institute (NCI)

Trials 2

today NCT05620342 · Ph 0 NCT03721068 · Ph 1
201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT05620342 Jun 2023 → Nov 2027 expected non-small cell lung carcinoma, small cell lung carcinoma UNC Lineberger Comprehensive Cancer Center Recruiting No outcome recorded
Phase 11 trial
Phase 1 NCT03721068 Feb 2019 → May 2030 expected neuroblastoma, osteosarcoma UNC Lineberger Comprehensive Cancer Center Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as iC9.GD2.CAR.IL-15 T cells “The short name for this treatment is iC9.GD2.CAR.IL-15 T cells therapy is an experimental therapy” NCT05620342 ↗
1

NCT03721068 ↗
Modality Cell therapy “CAR T-Cells” NCT03721068 ↗
Route Intravenous “iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection” NCT05620342 ↗